Mereo BioPharma Group Gelecekteki Büyüme
Future kriter kontrolleri 2/6
Mereo BioPharma Group's earnings are forecast to decline at 11.7% per annum while its annual revenue is expected to grow at 53.3% per year. EPS is expected to grow by 45.8% per annum.
Anahtar bilgiler
-11.7%
Kazanç büyüme oranı
45.8%
EPS büyüme oranı
Biotechs kazanç büyümesi | 27.1% |
Gelir büyüme oranı | 53.3% |
Gelecekteki özkaynak getirisi | n/a |
Analist kapsamı | Low |
Son güncelleme | 13 Aug 2024 |
Gelecekteki son büyüme güncellemeleri
Güncelleme yok
Recent updates
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?
Apr 07Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?
Nov 25Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat
Oct 17Rubric Capital boosts Mereo BioPharma board nominees slate to five
Oct 03Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
Sep 22Mereo activist investor Rubric asks board again to hold general meeting, nominate directors
Sep 14Mereo BioPharma Group regains compliance with Nasdaq's listing rule
Jul 05Mereo BioPharma: Activist Pressure In A Net-Net Biopharma
Jun 17Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development
Dec 08Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study
Apr 30Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | 41 | -40 | N/A | N/A | 3 |
12/31/2025 | 16 | -36 | N/A | N/A | 5 |
12/31/2024 | 15 | -23 | N/A | N/A | 5 |
6/30/2024 | 1 | -37 | -21 | -20 | N/A |
3/31/2024 | 10 | -26 | -21 | -20 | N/A |
12/31/2023 | 10 | -29 | -22 | -21 | N/A |
9/30/2023 | 10 | -32 | -34 | -33 | N/A |
6/30/2023 | 9 | -32 | -42 | -42 | N/A |
3/31/2023 | N/A | -42 | -46 | -46 | N/A |
12/31/2022 | N/A | -42 | -47 | -49 | N/A |
9/30/2022 | N/A | -31 | -42 | -43 | N/A |
6/30/2022 | N/A | -23 | -40 | -41 | N/A |
3/31/2022 | 24 | -4 | -25 | -26 | N/A |
12/31/2021 | 49 | 17 | -8 | -7 | N/A |
9/30/2021 | 49 | -10 | -9 | -8 | N/A |
6/30/2021 | 50 | -37 | -10 | -10 | N/A |
3/31/2021 | 25 | -131 | -23 | -25 | N/A |
12/31/2020 | N/A | -224 | -36 | -39 | N/A |
9/30/2020 | N/A | -198 | -35 | -37 | N/A |
6/30/2020 | N/A | -177 | -34 | -36 | N/A |
3/31/2020 | N/A | -111 | -46 | -47 | N/A |
12/31/2019 | N/A | -46 | -61 | -61 | N/A |
9/30/2019 | N/A | -41 | -50 | -50 | N/A |
6/30/2019 | N/A | -40 | -45 | -45 | N/A |
3/31/2019 | N/A | -41 | -38 | -38 | N/A |
12/31/2018 | N/A | -41 | -30 | -29 | N/A |
9/30/2018 | N/A | -42 | -41 | -39 | N/A |
6/30/2018 | N/A | -44 | -51 | -48 | N/A |
3/31/2018 | N/A | -50 | N/A | -48 | N/A |
12/31/2017 | N/A | -52 | N/A | -43 | N/A |
9/30/2017 | N/A | -50 | N/A | -41 | N/A |
6/30/2017 | N/A | -47 | N/A | -39 | N/A |
3/31/2017 | N/A | -41 | N/A | -37 | N/A |
12/31/2016 | N/A | -35 | N/A | -37 | N/A |
6/30/2016 | N/A | -39 | N/A | -25 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: MREO is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: MREO is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: MREO is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: MREO's revenue (53.3% per year) is forecast to grow faster than the US market (8.9% per year).
Yüksek Büyüme Geliri: MREO's revenue (53.3% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if MREO's Return on Equity is forecast to be high in 3 years time